Family-linked genetic frontotemporal dementia study for teens
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study follows young people ages 9 to 16 who have a close biological family member with genetic frontotemporal dementia (FTD). It aims to better understand this inherited condition and track participants over time. You may complete surveys and thinking/behavior assessments, and you may have brain MRI scans if you choose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can give consent for the study, and your substitute decision maker can consent if needed
- You are between 9 and 16 years old when you enroll (with follow-up until age 17)
- A parent or grandparent (first or second-degree biological relative) has joined the GENFI study or has a known genetic FTD mutation
- You have a parent/guardian who agrees it’s a good idea for you to join
- A study partner is available: usually your parent/guardian with regular contact who can help provide study information
- You and/or your parent/guardian can complete study assessments; brain MRI is optional if you meet MRI safety requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses brain scans to look for signs of inflammation in people with probable frontotemporal dementia, and in healthy volunteers for comparison. It may help researchers understand what’s happening in the brain and how it changes over time.
This study recruits adults who come from families with certain known gene changes linked to frontotemporal dementia. It aims to learn more about these inherited forms of dementia using brain scans and research blood testing, which will not provide personal results.
This study looks at complex brain and body changes in people with ALS and frontotemporal dementia (FTD), or related disorders. If you have one of these diagnoses—or a known gene mutation that can cause ALS/FTD—you may be able to help researchers learn how the conditions progress.
This trial tests a new gene therapy called AVB-101 for people with a specific genetic cause of frontotemporal dementia (FTD). The therapy is given as a one-time injection into the brain to potentially slow or stop the disease.
This study looks at testing (including brain scans) to figure out what type of frontotemporal dementia or related language/speech condition a person has. It may help by making diagnoses more accurate, which can guide better care.
This study is for adults who have a strong family history of ALS or FTD (like a parent or sibling with the disease) to help researchers understand how to prevent these conditions. It involves following you for about a year to track your health.
Hear when a new Frontotemporal Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.